Kiniksa Pharmaceuticals (KNSA) Competitors $21.76 -0.09 (-0.41%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$21.76 0.00 (0.00%) As of 07:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KNSA vs. TGTX, LEGN, AXSM, TLX, BPMC, KRYS, NUVL, CYTK, VRNA, and GRFSShould you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include TG Therapeutics (TGTX), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Krystal Biotech (KRYS), Nuvalent (NUVL), Cytokinetics (CYTK), Verona Pharma (VRNA), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Kiniksa Pharmaceuticals vs. TG Therapeutics Legend Biotech Axsome Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Krystal Biotech Nuvalent Cytokinetics Verona Pharma Grifols Kiniksa Pharmaceuticals (NASDAQ:KNSA) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk. Is KNSA or TGTX more profitable? Kiniksa Pharmaceuticals has a net margin of -2.36% compared to TG Therapeutics' net margin of -5.42%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat TG Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals-2.36% -7.31% -5.95% TG Therapeutics -5.42%-8.32%-3.40% Do analysts prefer KNSA or TGTX? Kiniksa Pharmaceuticals presently has a consensus price target of $37.17, indicating a potential upside of 70.80%. TG Therapeutics has a consensus price target of $40.67, indicating a potential upside of 3.37%. Given Kiniksa Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Kiniksa Pharmaceuticals is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Does the MarketBeat Community favor KNSA or TGTX? TG Therapeutics received 486 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 76.27% of users gave TG Therapeutics an outperform vote while only 65.28% of users gave Kiniksa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformKiniksa PharmaceuticalsOutperform Votes17365.28% Underperform Votes9234.72% TG TherapeuticsOutperform Votes65976.27% Underperform Votes20523.73% Which has more volatility and risk, KNSA or TGTX? Kiniksa Pharmaceuticals has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.13, indicating that its stock price is 113% more volatile than the S&P 500. Which has preferable valuation and earnings, KNSA or TGTX? Kiniksa Pharmaceuticals has higher revenue and earnings than TG Therapeutics. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals$423.24M3.73$14.08M-$0.61-35.67TG Therapeutics$329.00M18.78$12.67M$0.14281.00 Does the media prefer KNSA or TGTX? In the previous week, TG Therapeutics had 13 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 15 mentions for TG Therapeutics and 2 mentions for Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals' average media sentiment score of 1.78 beat TG Therapeutics' score of 1.16 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive TG Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in KNSA or TGTX? 54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 54.6% of Kiniksa Pharmaceuticals shares are owned by insiders. Comparatively, 10.5% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryKiniksa Pharmaceuticals beats TG Therapeutics on 10 of the 18 factors compared between the two stocks. Remove Ads Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition Export to ExcelMetricKiniksa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.58B$6.72B$5.53B$7.50BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-155.426.9923.1218.08Price / Sales3.73198.60360.0289.38Price / CashN/A65.6738.1634.64Price / Book3.495.926.473.99Net Income$14.08M$142.37M$3.21B$247.18M7 Day Performance-5.76%-7.24%-4.97%-4.25%1 Month Performance2.02%-10.45%-0.14%-6.87%1 Year Performance20.49%-14.58%6.19%-3.73% Kiniksa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals2.5901 of 5 stars$21.76-0.4%$37.17+70.8%+19.3%$1.58B$423.24M-155.42220Positive NewsTGTXTG Therapeutics2.8877 of 5 stars$42.61-0.9%$40.67-4.6%+171.9%$6.69B$329.00M-426.06290Positive NewsGap DownLEGNLegend Biotech2.5849 of 5 stars$36.33-1.7%$79.00+117.5%-41.7%$6.67B$627.24M-38.241,800Short Interest ↓News CoveragePositive NewsAXSMAxsome Therapeutics4.6661 of 5 stars$129.17+1.9%$167.36+29.6%+46.8%$6.30B$385.69M-21.56380Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap DownTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$18.24+2.5%$22.00+20.6%N/A$6.14B$783.21M0.00N/APositive NewsBPMCBlueprint Medicines2.7306 of 5 stars$95.27+7.4%$124.95+31.2%-5.6%$6.09B$508.82M-88.21640News CoveragePositive NewsGap DownKRYSKrystal Biotech4.5833 of 5 stars$194.44+3.9%$220.00+13.1%+0.1%$5.60B$290.52M65.03210News CoveragePositive NewsGap DownNUVLNuvalent2.3194 of 5 stars$77.14-1.1%$113.10+46.6%-7.7%$5.52BN/A-22.2340News CoveragePositive NewsGap DownCYTKCytokinetics3.9599 of 5 stars$46.57+2.5%$82.00+76.1%-42.9%$5.51B$18.47M-8.66250Gap DownVRNAVerona Pharma2.4524 of 5 stars$66.780.0%$69.14+3.5%+257.9%$5.40B$42.28M-34.7830Gap DownGRFSGrifols3.7462 of 5 stars$7.75-0.5%N/A+3.2%$5.33B$7.21B6.6226,300News Coverage Remove Ads Related Companies and Tools Related Companies TG Therapeutics Alternatives Legend Biotech Alternatives Axsome Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Blueprint Medicines Alternatives Krystal Biotech Alternatives Nuvalent Alternatives Cytokinetics Alternatives Verona Pharma Alternatives Grifols Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KNSA) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KNSA Stock Free KNSA Stock Alerts